Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03551821 · ClinicalTrials.gov registry record · Phase 2

Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata

A Phase 2 study of Alopecia Areata and Alopecia Totalis, sponsored by Aclaris Therapeutics.

Completed
Registry status
Phase 2
Development phase
1
Enrollment target
1
Study location

NCT03551821: Completed Phase 2 study of Alopecia Areata and Alopecia Totalis, sponsored by Aclaris Therapeutics.

NCT03551821 is a Phase 2 study of Alopecia Areata and Alopecia Totalis that has completed, run by Aclaris Therapeutics. The registered enrollment target is 1 participants, below the 1,955-participant average among 26 other Alopecia Areata trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03551821, a Phase 2 study of Alopecia Areata and Alopecia Totalis, has completed, sponsored by Aclaris Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
1 participants
Enrollment target
1
Study location

Study Summary

The main objective of this study is to assess the safety, tolerability and efficacy of ATI-50002 Topical Solution in subjects with unilateral or bilateral loss of eyebrow hair due to alopecia areata (AA), alopecia universalis (AU) or alopecia totalis (AT).

Primary Outcome

Determination of the amount of hair in the affected area. Clinician's Eyebrow Assessment Grade Descriptor 0 No eyebrow hair: No terminal hairs are visible in the affected area(s) 1. A little eyebrow hair: Occasional terminal hairs are visible in the affected area(s) 2. Some eyebrow hair: Numerous terminal hairs are visible in the affected area(s) 3. Most eyebrow hair: Mostly complete eyebrow regrowth with terminal hair in the affected area(s) 4. Full eyebrow hair: Complete eyebrow regrowth wi

Conditions Studied

Alopecia Areata Alopecia Totalis Alopecia Universalis

Interventions

  • DRUG ATI-50002

Study Locations (1)

Florida

  • Aclaris Investigator Site - Boynton Beach

Trial Details

FieldValue
Enrollment Target 1 participants
Start Date 2018-04-11
Est. Completion 2018-11-06
Phase Phase 2
Aclaris Therapeutics

33 total trials

What the finished NCT03551821 record still lists

NCT03551821 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 1,955-participant average among 26 other Alopecia Areata trials with a reported enrollment target (100% lower).

The record links to 3 conditions, with Alopecia Areata appearing as the primary indexed condition, and to 1 intervention - of which ATI-50002 is the first listed.

NCT03551821 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT03551821 about?

NCT03551821 is a clinical study titled "Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata". The main objective of this study is to assess the safety, tolerability and efficacy of ATI-50002 Topical Solution in subjects with unilateral or bilateral loss of eyebrow hair due to alopecia areata (AA), alopecia universalis (AU) or alopecia totalis (AT).

What is the current status of trial NCT03551821?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2018-04-11. Estimated completion is 2018-11-06.

What conditions does trial NCT03551821 study?

This clinical trial studies the following conditions: Alopecia Areata, Alopecia Totalis, Alopecia Universalis.

What interventions are being tested in trial NCT03551821?

The interventions under investigation include: ATI-50002 (DRUG).

Who is sponsoring clinical trial NCT03551821?

This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03551821 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alopecia Areata

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03551821's enrollment target sits among peer trials

1 27th of 26 the lowest of 26 other Alopecia Areata trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Alopecia Areata trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03551821, the US trial registry maintained by the National Library of Medicine. NCT03551821 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.